Skip to main content
. 2021 Aug 26;12:724429. doi: 10.3389/fimmu.2021.724429

Figure 7.

Figure 7

Four recurrence-risk subgroups according to the combination of CD86/CD163 ratio and tumor stage in the training (A) and validation (B) cohorts.